| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | positive regulation of mRNA splicing, via spliceosome | 1.98e-04 | 44 | 10 | 2 | GO:0048026 | |
| GeneOntologyBiologicalProcess | positive regulation of mRNA processing | 2.46e-04 | 49 | 10 | 2 | GO:0050685 | |
| GeneOntologyBiologicalProcess | positive regulation of RNA splicing | 4.07e-04 | 63 | 10 | 2 | GO:0033120 | |
| GeneOntologyBiologicalProcess | mRNA splicing, via spliceosome | 5.68e-04 | 358 | 10 | 3 | GO:0000398 | |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 5.68e-04 | 358 | 10 | 3 | GO:0000377 | |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions | 5.87e-04 | 362 | 10 | 3 | GO:0000375 | |
| GeneOntologyBiologicalProcess | RNA splicing | 1.51e-03 | 502 | 10 | 3 | GO:0008380 | |
| GeneOntologyBiologicalProcess | regulation of mRNA splicing, via spliceosome | 1.69e-03 | 129 | 10 | 2 | GO:0048024 | |
| GeneOntologyBiologicalProcess | mRNA processing | 1.98e-03 | 551 | 10 | 3 | GO:0006397 | |
| GeneOntologyBiologicalProcess | bone mineralization | 2.25e-03 | 149 | 10 | 2 | GO:0030282 | |
| GeneOntologyBiologicalProcess | regulation of mRNA processing | 2.52e-03 | 158 | 10 | 2 | GO:0050684 | |
| GeneOntologyBiologicalProcess | biomineral tissue development | 4.12e-03 | 203 | 10 | 2 | GO:0031214 | |
| GeneOntologyBiologicalProcess | regulation of RNA splicing | 4.28e-03 | 207 | 10 | 2 | GO:0043484 | |
| MousePheno | abnormal lung development | 1.50e-03 | 142 | 6 | 2 | MP:0001176 | |
| MousePheno | abnormal respiratory system development | 1.89e-03 | 160 | 6 | 2 | MP:0003115 | |
| Domain | BAT2_N | 9.46e-07 | 3 | 11 | 2 | IPR009738 | |
| Domain | PRRC2 | 9.46e-07 | 3 | 11 | 2 | IPR033184 | |
| Domain | BAT2_N | 9.46e-07 | 3 | 11 | 2 | PF07001 | |
| Domain | RRM_1 | 6.35e-03 | 208 | 11 | 2 | PF00076 | |
| Domain | RRM | 6.90e-03 | 217 | 11 | 2 | SM00360 | |
| Domain | RRM_dom | 7.53e-03 | 227 | 11 | 2 | IPR000504 | |
| Domain | RRM | 7.72e-03 | 230 | 11 | 2 | PS50102 | |
| Domain | - | 8.65e-03 | 244 | 11 | 2 | 3.30.70.330 | |
| Domain | Nucleotide-bd_a/b_plait | 9.63e-03 | 258 | 11 | 2 | IPR012677 | |
| Pathway | WP_MRNA_PROCESSING | 1.03e-03 | 451 | 7 | 3 | MM15946 | |
| Pathway | WP_VEGFAVEGFR2_SIGNALING | 1.77e-02 | 431 | 7 | 2 | M39729 | |
| Pubmed | 4.64e-09 | 223 | 11 | 5 | 20020773 | ||
| Pubmed | SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9. | 9.63e-09 | 258 | 11 | 5 | 37794589 | |
| Pubmed | PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. | 2.28e-08 | 678 | 11 | 6 | 30209976 | |
| Pubmed | 3.08e-08 | 713 | 11 | 6 | 29802200 | ||
| Pubmed | 4.18e-08 | 1371 | 11 | 7 | 36244648 | ||
| Pubmed | The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. | 6.41e-08 | 807 | 11 | 6 | 22681889 | |
| Pubmed | TERRA transcripts are bound by a complex array of RNA-binding proteins. | 7.68e-08 | 28 | 11 | 3 | 20975687 | |
| Pubmed | The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. | 9.88e-08 | 147 | 11 | 4 | 28977470 | |
| Pubmed | A protein-RNA interaction atlas of the ribosome biogenesis factor AATF. | 1.46e-07 | 162 | 11 | 4 | 31363146 | |
| Pubmed | 1.86e-07 | 172 | 11 | 4 | 26336360 | ||
| Pubmed | 4.19e-07 | 551 | 11 | 5 | 34728620 | ||
| Pubmed | 7.50e-07 | 244 | 11 | 4 | 29884807 | ||
| Pubmed | 9.81e-07 | 655 | 11 | 5 | 35819319 | ||
| Pubmed | 1.19e-06 | 274 | 11 | 4 | 34244482 | ||
| Pubmed | Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. | 1.50e-06 | 714 | 11 | 5 | 28302793 | |
| Pubmed | 1.68e-06 | 731 | 11 | 5 | 29298432 | ||
| Pubmed | 1.93e-06 | 1440 | 11 | 6 | 30833792 | ||
| Pubmed | 5.28e-06 | 399 | 11 | 4 | 35987950 | ||
| Pubmed | 6.48e-06 | 963 | 11 | 5 | 28671696 | ||
| Pubmed | 6.81e-06 | 122 | 11 | 3 | 29530978 | ||
| Pubmed | 1.23e-05 | 17 | 11 | 2 | 37072811 | ||
| Pubmed | 1.25e-05 | 1103 | 11 | 5 | 34189442 | ||
| Pubmed | 1.32e-05 | 503 | 11 | 4 | 16964243 | ||
| Pubmed | 2.09e-05 | 22 | 11 | 2 | 38507412 | ||
| Pubmed | CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. | 2.72e-05 | 605 | 11 | 4 | 28977666 | |
| Pubmed | LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells. | 3.36e-05 | 639 | 11 | 4 | 23443559 | |
| Pubmed | Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. | 3.94e-05 | 30 | 11 | 2 | 15782174 | |
| Pubmed | BioID-based Identification of Skp Cullin F-box (SCF)β-TrCP1/2 E3 Ligase Substrates. | 4.30e-05 | 226 | 11 | 3 | 25900982 | |
| Pubmed | 4.40e-05 | 1431 | 11 | 5 | 37142655 | ||
| Pubmed | A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation. | 5.47e-05 | 724 | 11 | 4 | 36232890 | |
| Pubmed | 5.50e-05 | 725 | 11 | 4 | 27025967 | ||
| Pubmed | 5.87e-05 | 251 | 11 | 3 | 31076518 | ||
| Pubmed | 6.52e-05 | 260 | 11 | 3 | 36199071 | ||
| Pubmed | The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis. | 6.57e-05 | 759 | 11 | 4 | 35915203 | |
| Pubmed | 7.41e-05 | 41 | 11 | 2 | 8724849 | ||
| Pubmed | 8.56e-05 | 285 | 11 | 3 | 32838362 | ||
| Pubmed | ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure. | 1.15e-04 | 315 | 11 | 3 | 26777405 | |
| Pubmed | Interactome of vertebrate GAF/ThPOK reveals its diverse functions in gene regulation and DNA repair. | 1.22e-04 | 321 | 11 | 3 | 32098917 | |
| Pubmed | Analysis of HIV-1 Gag protein interactions via biotin ligase tagging. | 1.29e-04 | 54 | 11 | 2 | 25631074 | |
| Pubmed | Elucidation of the BMI1 interactome identifies novel regulatory roles in glioblastoma. | 1.31e-04 | 329 | 11 | 3 | 34316702 | |
| Pubmed | Global phosphoproteome of HT-29 human colon adenocarcinoma cells. | 1.54e-04 | 59 | 11 | 2 | 16083285 | |
| Pubmed | The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers. | 1.59e-04 | 954 | 11 | 4 | 36373674 | |
| Pubmed | 1.59e-04 | 60 | 11 | 2 | 26472337 | ||
| Pubmed | 1.70e-04 | 971 | 11 | 4 | 33306668 | ||
| Pubmed | 1.71e-04 | 360 | 11 | 3 | 33111431 | ||
| Pubmed | SR protein kinases promote splicing of nonconsensus introns. | 1.72e-04 | 361 | 11 | 3 | 26167880 | |
| Pubmed | Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates. | 1.93e-04 | 66 | 11 | 2 | 24811749 | |
| Pubmed | Identification of a USP9X Substrate NFX1-123 by SILAC-Based Quantitative Proteomics. | 2.06e-04 | 384 | 11 | 3 | 31059266 | |
| Pubmed | 2.11e-04 | 69 | 11 | 2 | 35264565 | ||
| Pubmed | 2.30e-04 | 72 | 11 | 2 | 33106477 | ||
| Pubmed | 2.43e-04 | 74 | 11 | 2 | 33989516 | ||
| Pubmed | Transcription factor protein interactomes reveal genetic determinants in heart disease. | 2.52e-04 | 411 | 11 | 3 | 35182466 | |
| Pubmed | TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. | 2.88e-04 | 430 | 11 | 3 | 38172120 | |
| Interaction | PRMT8 interactions | 1.50e-09 | 104 | 11 | 5 | int:PRMT8 | |
| Interaction | DMRT2 interactions | 3.93e-07 | 28 | 11 | 3 | int:DMRT2 | |
| Interaction | RC3H2 interactions | 5.15e-07 | 667 | 11 | 6 | int:RC3H2 | |
| Interaction | RC3H1 interactions | 5.62e-07 | 677 | 11 | 6 | int:RC3H1 | |
| Interaction | IGF2BP2 interactions | 7.18e-07 | 357 | 11 | 5 | int:IGF2BP2 | |
| Interaction | CASC3 interactions | 7.50e-07 | 142 | 11 | 4 | int:CASC3 | |
| Interaction | MKRN2 interactions | 1.04e-06 | 385 | 11 | 5 | int:MKRN2 | |
| Interaction | RBMXL1 interactions | 1.07e-06 | 155 | 11 | 4 | int:RBMXL1 | |
| Interaction | ALG13 interactions | 2.07e-06 | 183 | 11 | 4 | int:ALG13 | |
| Interaction | CIT interactions | 2.51e-06 | 1450 | 11 | 7 | int:CIT | |
| Interaction | PAIP2B interactions | 2.63e-06 | 52 | 11 | 3 | int:PAIP2B | |
| Interaction | PRMT1 interactions | 3.57e-06 | 929 | 11 | 6 | int:PRMT1 | |
| Interaction | TARDBP interactions | 4.56e-06 | 520 | 11 | 5 | int:TARDBP | |
| Interaction | SNRNP70 interactions | 4.99e-06 | 984 | 11 | 6 | int:SNRNP70 | |
| Interaction | LARP4B interactions | 6.06e-06 | 240 | 11 | 4 | int:LARP4B | |
| Interaction | PUM1 interactions | 1.23e-05 | 287 | 11 | 4 | int:PUM1 | |
| Interaction | FXR1 interactions | 1.67e-05 | 679 | 11 | 5 | int:FXR1 | |
| Interaction | RNF113A interactions | 1.83e-05 | 692 | 11 | 5 | int:RNF113A | |
| Interaction | GLDC interactions | 1.91e-05 | 321 | 11 | 4 | int:GLDC | |
| Interaction | CEBPA interactions | 1.94e-05 | 1245 | 11 | 6 | int:CEBPA | |
| Interaction | RBM42 interactions | 2.15e-05 | 331 | 11 | 4 | int:RBM42 | |
| Interaction | MOV10 interactions | 2.45e-05 | 1297 | 11 | 6 | int:MOV10 | |
| Interaction | FUS interactions | 2.82e-05 | 757 | 11 | 5 | int:FUS | |
| Interaction | WDR77 interactions | 3.03e-05 | 361 | 11 | 4 | int:WDR77 | |
| Interaction | LINC00240 interactions | 3.24e-05 | 16 | 11 | 2 | int:LINC00240 | |
| Interaction | MYCN interactions | 3.39e-05 | 1373 | 11 | 6 | int:MYCN | |
| Interaction | AATF interactions | 3.55e-05 | 376 | 11 | 4 | int:AATF | |
| Interaction | MRPS9 interactions | 3.77e-05 | 382 | 11 | 4 | int:MRPS9 | |
| Interaction | R3HDM2 interactions | 4.07e-05 | 129 | 11 | 3 | int:R3HDM2 | |
| Interaction | TRIM56 interactions | 4.87e-05 | 137 | 11 | 3 | int:TRIM56 | |
| Interaction | SUPV3L1 interactions | 5.09e-05 | 139 | 11 | 3 | int:SUPV3L1 | |
| Interaction | PTCD1 interactions | 5.42e-05 | 142 | 11 | 3 | int:PTCD1 | |
| Interaction | ZC3H18 interactions | 5.72e-05 | 877 | 11 | 5 | int:ZC3H18 | |
| Interaction | DAZL interactions | 5.77e-05 | 145 | 11 | 3 | int:DAZL | |
| Interaction | SEC16A interactions | 5.77e-05 | 426 | 11 | 4 | int:SEC16A | |
| Interaction | CPEB1 interactions | 5.89e-05 | 146 | 11 | 3 | int:CPEB1 | |
| Interaction | CAND1 interactions | 6.28e-05 | 894 | 11 | 5 | int:CAND1 | |
| Interaction | CPEB4 interactions | 7.17e-05 | 156 | 11 | 3 | int:CPEB4 | |
| Interaction | RPA4 interactions | 7.27e-05 | 452 | 11 | 4 | int:RPA4 | |
| Interaction | HNRNPCL1 interactions | 7.88e-05 | 161 | 11 | 3 | int:HNRNPCL1 | |
| Interaction | HNRNPA1 interactions | 8.18e-05 | 945 | 11 | 5 | int:HNRNPA1 | |
| Interaction | SNRPA interactions | 9.33e-05 | 482 | 11 | 4 | int:SNRPA | |
| Interaction | ZCCHC3 interactions | 9.42e-05 | 171 | 11 | 3 | int:ZCCHC3 | |
| Interaction | ZFP36 interactions | 1.11e-04 | 181 | 11 | 3 | int:ZFP36 | |
| Interaction | IGF2BP1 interactions | 1.14e-04 | 508 | 11 | 4 | int:IGF2BP1 | |
| Interaction | PSPC1 interactions | 1.21e-04 | 515 | 11 | 4 | int:PSPC1 | |
| Interaction | ELAVL2 interactions | 1.25e-04 | 188 | 11 | 3 | int:ELAVL2 | |
| Interaction | CDKN2AIPNL interactions | 1.25e-04 | 31 | 11 | 2 | int:CDKN2AIPNL | |
| Interaction | RBM39 interactions | 1.30e-04 | 1042 | 11 | 5 | int:RBM39 | |
| Interaction | FAM120C interactions | 1.31e-04 | 191 | 11 | 3 | int:FAM120C | |
| Interaction | FMR1 interactions | 1.41e-04 | 536 | 11 | 4 | int:FMR1 | |
| Interaction | RBM47 interactions | 1.59e-04 | 204 | 11 | 3 | int:RBM47 | |
| Interaction | RBMS1 interactions | 1.66e-04 | 207 | 11 | 3 | int:RBMS1 | |
| Interaction | TDRD3 interactions | 1.78e-04 | 212 | 11 | 3 | int:TDRD3 | |
| Interaction | MRPL15 interactions | 1.83e-04 | 214 | 11 | 3 | int:MRPL15 | |
| Interaction | ZC3H11A interactions | 1.85e-04 | 215 | 11 | 3 | int:ZC3H11A | |
| Interaction | ZC3H7A interactions | 1.85e-04 | 215 | 11 | 3 | int:ZC3H7A | |
| Interaction | UPF1 interactions | 1.92e-04 | 581 | 11 | 4 | int:UPF1 | |
| Interaction | MEX3B interactions | 2.04e-04 | 222 | 11 | 3 | int:MEX3B | |
| Interaction | RPL5 interactions | 2.26e-04 | 606 | 11 | 4 | int:RPL5 | |
| Interaction | FZR1 interactions | 2.27e-04 | 1172 | 11 | 5 | int:FZR1 | |
| Interaction | NGRN interactions | 2.41e-04 | 235 | 11 | 3 | int:NGRN | |
| Interaction | OTUD4 interactions | 2.44e-04 | 236 | 11 | 3 | int:OTUD4 | |
| Interaction | YTHDF3 interactions | 2.76e-04 | 246 | 11 | 3 | int:YTHDF3 | |
| Interaction | PRR3 interactions | 2.76e-04 | 246 | 11 | 3 | int:PRR3 | |
| Interaction | CHCHD2 interactions | 2.82e-04 | 248 | 11 | 3 | int:CHCHD2 | |
| Interaction | MATR3 interactions | 3.04e-04 | 655 | 11 | 4 | int:MATR3 | |
| Interaction | BMI1 interactions | 3.11e-04 | 659 | 11 | 4 | int:BMI1 | |
| Interaction | HELZ interactions | 3.14e-04 | 257 | 11 | 3 | int:HELZ | |
| Interaction | LSM14A interactions | 3.24e-04 | 260 | 11 | 3 | int:LSM14A | |
| Interaction | CAMK2A interactions | 3.99e-04 | 279 | 11 | 3 | int:CAMK2A | |
| Interaction | CSDE1 interactions | 4.20e-04 | 284 | 11 | 3 | int:CSDE1 | |
| Interaction | SRPK2 interactions | 4.29e-04 | 717 | 11 | 4 | int:SRPK2 | |
| Interaction | DDX21 interactions | 4.32e-04 | 718 | 11 | 4 | int:DDX21 | |
| Interaction | CELF1 interactions | 4.38e-04 | 288 | 11 | 3 | int:CELF1 | |
| Interaction | SYNCRIP interactions | 4.38e-04 | 721 | 11 | 4 | int:SYNCRIP | |
| Interaction | MRPS2 interactions | 4.47e-04 | 290 | 11 | 3 | int:MRPS2 | |
| Interaction | KLF15 interactions | 4.47e-04 | 290 | 11 | 3 | int:KLF15 | |
| Interaction | ZFAND2B interactions | 4.71e-04 | 60 | 11 | 2 | int:ZFAND2B | |
| Interaction | FUBP3 interactions | 4.79e-04 | 297 | 11 | 3 | int:FUBP3 | |
| Interaction | UBAP2L interactions | 4.84e-04 | 298 | 11 | 3 | int:UBAP2L | |
| Interaction | EIF4ENIF1 interactions | 4.93e-04 | 300 | 11 | 3 | int:EIF4ENIF1 | |
| Interaction | YTHDF1 interactions | 5.03e-04 | 302 | 11 | 3 | int:YTHDF1 | |
| Interaction | DHX36 interactions | 5.08e-04 | 303 | 11 | 3 | int:DHX36 | |
| Interaction | KCTD13 interactions | 5.10e-04 | 1394 | 11 | 5 | int:KCTD13 | |
| Interaction | HNRNPA2B1 interactions | 5.20e-04 | 754 | 11 | 4 | int:HNRNPA2B1 | |
| Interaction | CHD3 interactions | 5.28e-04 | 757 | 11 | 4 | int:CHD3 | |
| Interaction | MRPS31 interactions | 5.43e-04 | 310 | 11 | 3 | int:MRPS31 | |
| Interaction | YTHDF2 interactions | 5.53e-04 | 312 | 11 | 3 | int:YTHDF2 | |
| Interaction | ATXN2 interactions | 5.53e-04 | 312 | 11 | 3 | int:ATXN2 | |
| Interaction | BTRC interactions | 5.77e-04 | 775 | 11 | 4 | int:BTRC | |
| Interaction | DAP3 interactions | 6.17e-04 | 324 | 11 | 3 | int:DAP3 | |
| Interaction | MAD2L2 interactions | 6.23e-04 | 325 | 11 | 3 | int:MAD2L2 | |
| Interaction | KLF8 interactions | 6.45e-04 | 329 | 11 | 3 | int:KLF8 | |
| Interaction | CHCHD10 interactions | 7.35e-04 | 75 | 11 | 2 | int:CHCHD10 | |
| Interaction | FAM120A interactions | 7.66e-04 | 349 | 11 | 3 | int:FAM120A | |
| Interaction | HNRNPK interactions | 8.28e-04 | 853 | 11 | 4 | int:HNRNPK | |
| Interaction | HDLBP interactions | 8.36e-04 | 855 | 11 | 4 | int:HDLBP | |
| Interaction | DUSP11 interactions | 8.78e-04 | 82 | 11 | 2 | int:DUSP11 | |
| Interaction | ZBTB7B interactions | 8.80e-04 | 366 | 11 | 3 | int:ZBTB7B | |
| GeneFamily | RNA binding motif containing | 1.35e-03 | 213 | 5 | 2 | 725 | |
| Coexpression | GSE25146_UNSTIM_VS_HELIOBACTER_PYLORI_LPS_STIM_AGS_CELL_DN | 3.97e-05 | 166 | 11 | 3 | M8129 | |
| Coexpression | MCDOWELL_ACUTE_LUNG_INJURY_UP | 1.71e-04 | 47 | 11 | 2 | M1527 | |
| Coexpression | MCDOWELL_ACUTE_LUNG_INJURY_UP | 1.79e-04 | 48 | 11 | 2 | MM1169 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-mesenchymal_stem_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.23e-05 | 192 | 11 | 3 | 11088878043a6ff95ba1970361256a82e434b80a | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.29e-05 | 195 | 11 | 3 | 5c86fddd6d0530beecf45ea5ba6b823123847696 | |
| ToppCell | (05)_Secretory-(2)_GFP_FOXI1|(05)_Secretory / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | d72d87e1e530ed894c0ad5e7b5b2b1d6b59fa098 | |
| ToppCell | (03)_KRT6B+-(2)_GFP_FOXI1|(03)_KRT6B+ / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | c425e7975f492ed5cfcca022248adb627e1d27d4 | |
| ToppCell | (02)_MMP9/10+-(2)_GFP_FOXI1|(02)_MMP9/10+ / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | 18a7f9ced4364f45b184bd529f32ef02c27779d3 | |
| ToppCell | (10)_Ciliated-(2)_GFP_FOXI1|(10)_Ciliated / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | 61b1ed2db71b96157b92b7535d1955a4033098da | |
| ToppCell | (04)_Interm._basal>secr.-(2)_GFP_FOXI1|(04)_Interm._basal>secr. / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | 53ca3861f9e00dab3f3fbefb0837857ee39ab084 | |
| ToppCell | (00)_Basal-(2)_GFP_FOXI1|(00)_Basal / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | 19674e1eaeb51e4196d847cb62aa437c852951d3 | |
| ToppCell | (09)_Interm._secr.>cil.-(2)_GFP_FOXI1|(09)_Interm._secr.>cil. / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | fc680f85ebd3bab4c72876a19a461b0afb5f51ce | |
| ToppCell | (01)_IL1RL1+-(2)_GFP_FOXI1|(01)_IL1RL1+ / shred by cell type by condition | 1.37e-05 | 199 | 11 | 3 | a2f7d0cabf35b80fe239fae34a77bf9344d5d743 | |
| ToppCell | COVID-19-COVID-19_Mild|COVID-19 / Disease, condition lineage and cell class | 1.39e-05 | 200 | 11 | 3 | 62c25042086f1afd1102e0720e933c2e476468fd | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Undifferentiated_Pleomorphic_Sarcoma-3|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 2.25e-04 | 92 | 11 | 2 | f646685fd9c6601b48f1855b6edc47626ea666b0 | |
| ToppCell | normal_Lymph_Node-B_lymphocytes-Undetermined|normal_Lymph_Node / Location, Cell class and cell subclass | 6.94e-04 | 162 | 11 | 2 | 91ac35ae7fde411cd6a44e715a33dac62419cab8 | |
| ToppCell | TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_Diffuse-6|TCGA-Stomach / Sample_Type by Project: Shred V9 | 7.02e-04 | 163 | 11 | 2 | c1a98d6776b685f20dde049715233e5c73ce3244 | |
| ToppCell | NS-critical-d_0-4-Epithelial-Secretory|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 7.54e-04 | 169 | 11 | 2 | aec97583b23112060437b619cb429dc32f29285f | |
| ToppCell | E17.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 7.63e-04 | 170 | 11 | 2 | 7fa022471e14ac8a3bc147c793368a4d56a8e591 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.4|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.90e-04 | 173 | 11 | 2 | 176b956e71d98e8275d698b39437fc326e5fe449 | |
| ToppCell | droplet-Lung-18m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l14|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 7.99e-04 | 174 | 11 | 2 | 02ab165b064acb91f2d3f59cc5be195899d61a83 | |
| ToppCell | (00)_Basal-(2)_48hpi|(00)_Basal / shred by cell type and Timepoint | 8.18e-04 | 176 | 11 | 2 | 0f6770296d7fa453ffbf6ca6d5fdebc888f6eb60 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.36e-04 | 178 | 11 | 2 | 01dafd19de04eff459253eaa9a35debf8f3deedf | |
| ToppCell | NS|World / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.55e-04 | 180 | 11 | 2 | 8472dcce7bc0b7ce428ec17ddf0018f3258f78d2 | |
| ToppCell | droplet-Marrow-nan-3m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.93e-04 | 184 | 11 | 2 | 1154a5ad7b8512272b7476f949ddac350910bfb7 | |
| ToppCell | droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.42e-04 | 189 | 11 | 2 | 562f8bf5a7d38afb4a8f2415d617d5f79cfb7e3f | |
| ToppCell | droplet-Heart-HEART_(ALL_MINUS_AORTA)|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.42e-04 | 189 | 11 | 2 | 270dd4a0fc5260288fe6829837942c78b40ecec4 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-A|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 9.52e-04 | 190 | 11 | 2 | 63018acb7ad80415e861643162abdc2e55968ee4 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.62e-04 | 191 | 11 | 2 | 7d1595e616f6f111fc2f5bc1b179c5d67d624cc9 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.62e-04 | 191 | 11 | 2 | 1ecd9849d14d5ebf3daf610e83fb50820cafd3ed | |
| ToppCell | droplet-Tongue-TONGUE-1m-Epithelial-suprabasal_differentiating|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.82e-04 | 193 | 11 | 2 | 49f4fbec91acda4727703e0e359ed780eefb8a22 | |
| ToppCell | COVID-19_Mild|World / Disease condition and Cell class | 9.82e-04 | 193 | 11 | 2 | 7256a5a491536c525b31ae96d47ab5c6303cb73a | |
| ToppCell | TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6|TCGA-Prostate / Sample_Type by Project: Shred V9 | 9.82e-04 | 193 | 11 | 2 | abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.92e-04 | 194 | 11 | 2 | e3d63874111d1e8da3977329426e4dcf68d6de87 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.00e-03 | 195 | 11 | 2 | 7796ea9247f4c63762f0de8490fed08b9717fa23 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.00e-03 | 195 | 11 | 2 | 3e519cffa6144a62b06124642a14c9ff39b76554 | |
| ToppCell | Control-Classical_Monocyte-cMono_2|Classical_Monocyte / Disease condition and Cell class | 1.02e-03 | 197 | 11 | 2 | eb7610c9496a95a5fd866e16abcbc39b83abe617 | |
| ToppCell | COVID-19_Mild|World / Disease group, lineage and cell class | 1.02e-03 | 197 | 11 | 2 | 5c33454b10023decd2f5ccda9229b6512659711e | |
| ToppCell | H1299-infected-SARSCoV2|infected / Cell line, Condition and Strain | 1.02e-03 | 197 | 11 | 2 | 0fa3e4cf93e77d78b1f97b906c5b13ca741ae17e | |
| ToppCell | COVID-19_Mild|World / Disease condition and Cell class | 1.03e-03 | 198 | 11 | 2 | 61ceb2245b6cb58e308b999a61d218c89dbc615e | |
| ToppCell | LAM-Endothelial-LymEndo|Endothelial / Condition, Lineage and Cell class | 1.03e-03 | 198 | 11 | 2 | ba64b1c95dfaa995045239d412e725596f6c482e | |
| ToppCell | PBMC_fresh-frozen|World / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.03e-03 | 198 | 11 | 2 | dcc223a0396b8b673e4ed8c6733ec6cd74e9a03a | |
| ToppCell | PBMC-Mild|PBMC / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.03e-03 | 198 | 11 | 2 | 44417089b62056269cac38d3134ff209c05b7007 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Newborn-35|World / Primary Cells by Cluster | 1.03e-03 | 198 | 11 | 2 | de5214a85fe017eb23d4aa8af624464f062ec57e | |
| ToppCell | PBMC|World / Compartment, Disease Groups and Clusters | 1.03e-03 | 198 | 11 | 2 | 84f5b43dad0c57556171dbc0b799735654582ecf | |
| ToppCell | PBMC-Mild|PBMC / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.03e-03 | 198 | 11 | 2 | 28ef3fc4c17dcb765537b75917f7db78baa522db | |
| ToppCell | megakaryocytic-CD34+_Megakaryoblast|megakaryocytic / Lineage and Cell class | 1.04e-03 | 199 | 11 | 2 | 99a65887d3c8a2cde26693dd74404b101bba9d58 | |
| ToppCell | severe|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.05e-03 | 200 | 11 | 2 | accc618d6b960bff30cb531c1226295bfc8650f6 | |
| ToppCell | TCGA-Bile_Duct-Primary_Tumor-Cholangiocarcinoma|TCGA-Bile_Duct / Sample_Type by Project: Shred V9 | 1.05e-03 | 200 | 11 | 2 | ad2a6da0b1ae7a9212a3c91e5eec4baa7481d8dc | |
| ToppCell | TCGA-Bile_Duct-Primary_Tumor|TCGA-Bile_Duct / Sample_Type by Project: Shred V9 | 1.05e-03 | 200 | 11 | 2 | 0350e5ffd36033099b7e32a1fdd790fff99790dc | |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.05e-03 | 200 | 11 | 2 | 12f1685ce8f218433068e090c9d839cd5a1910bf | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuronal-Intermediate|6m / Sample Type, Dataset, Time_group, and Cell type. | 1.05e-03 | 200 | 11 | 2 | 7c261e39ac30b318511373ab7302aa53b8b81b9c | |
| ToppCell | Sigmoid-Macrophage-LYVE1_Macrophage|Macrophage / Region, Cell class and subclass | 1.05e-03 | 200 | 11 | 2 | cdb3f242d0c80b4eb9044f59156443e77fb81a1d | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 1.05e-03 | 200 | 11 | 2 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| Computational | Neighborhood of BNIP2 | 1.45e-04 | 34 | 6 | 2 | GNF2_BNIP2 | |
| Computational | Neighborhood of PPP6C | 1.91e-04 | 39 | 6 | 2 | GNF2_PPP6C | |
| Computational | Neighborhood of DDX5 | 5.32e-04 | 65 | 6 | 2 | GCM_DDX5 | |
| Drug | 3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol | 6.98e-06 | 314 | 10 | 4 | ctd:C572491 | |
| Drug | FCE 22101 | 1.14e-05 | 12 | 10 | 2 | CID000065633 | |
| Drug | 12-MTA | 1.35e-05 | 13 | 10 | 2 | CID000021672 | |
| Drug | benzalkonium | 3.12e-05 | 148 | 10 | 3 | CID000007681 | |
| Drug | Norethynodrel [68-23-5]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 6.78e-05 | 192 | 10 | 3 | 1696_UP | |
| Drug | Flutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A | 6.99e-05 | 194 | 10 | 3 | 4361_DN | |
| Drug | propyl gallate | 2.55e-04 | 55 | 10 | 2 | CID000004947 | |
| Drug | penicillin | 2.64e-04 | 56 | 10 | 2 | CID000002349 | |
| Drug | AC1L1GIB | 6.66e-04 | 89 | 10 | 2 | CID000003695 | |
| Drug | hygromycin A | 8.40e-04 | 100 | 10 | 2 | CID006433481 | |
| Drug | dhpta | 9.08e-04 | 104 | 10 | 2 | CID000018465 | |
| Drug | Alstonine hydrochloride | 1.13e-03 | 116 | 10 | 2 | CID000023039 | |
| Drug | potassium phosphate | 1.23e-03 | 121 | 10 | 2 | CID000024450 | |
| Drug | tetradecylthioacetic acid | 1.37e-03 | 128 | 10 | 2 | CID000114924 | |
| Drug | (+/-)-Jasmonic Acid | 2.08e-03 | 158 | 10 | 2 | CID000105087 | |
| Drug | hydroxyapatite | 2.43e-03 | 171 | 10 | 2 | CID000014781 | |
| Drug | Cortisporin | 2.60e-03 | 177 | 10 | 2 | CID000004454 | |
| Disease | anxiety measurement | 3.66e-04 | 108 | 8 | 2 | EFO_0009863 | |
| Disease | irritable bowel syndrome | 5.38e-04 | 131 | 8 | 2 | EFO_0000555 | |
| Disease | health study participation | 1.19e-03 | 195 | 8 | 2 | EFO_0010130 | |
| Disease | Inguinal hernia | 2.54e-03 | 287 | 8 | 2 | HP_0000023 | |
| Disease | platelet component distribution width | 1.65e-02 | 755 | 8 | 2 | EFO_0007984 | |
| Disease | Liver Cirrhosis, Experimental | 1.73e-02 | 774 | 8 | 2 | C0023893 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| RPGGYGYGYGRSRDY | 121 | P98179 | |
| PGNRGGYRNFYDRYR | 681 | Q1KMD3 | |
| TFGRGGRYYGRGYKN | 996 | Q9NZB2 | |
| GMRRPYGYRGRGRGY | 66 | Q9NYF8 | |
| GGRYRPGYGTGYFQY | 196 | P28300 | |
| SFRRLGYGCGYGGYR | 31 | Q3SYF9 | |
| FLRRIGRFGYGYGPY | 26 | P02808 | |
| GYYGRERKIGRAGYR | 211 | Q7Z5M5 | |
| PDQGYRGRGRGEYYS | 1181 | Q9Y520 | |
| YFARGRGFRGTYGGR | 1031 | P48634 | |
| HRYGGGGRYEEYRGR | 771 | Q8N7X1 |